PDF(Pubmed)
Abstract：
UNASSIGNED: To investigate the clinicopathological characteristics, diagnosis and key points in the differential diagnosis of patients with gastric cancer (GC) with features of a submucosal tumour (GCSMT).
UNASSIGNED: The clinical presentation and imaging findings of four GCSMT cases diagnosed at our centre from 2016 to 2021 were observed and their clinicopathological outcomes were analysed. The related literature was reviewed. Based on our collected data and the related literature, a total of 31 cases of GCSMT can be summarized.
UNASSIGNED: 22 out of 31 cases did not present obvious symptoms and were accidentally discovered during gastroscopic examination. Only 10 patients experienced symptoms such as gastric discomfort, upper abdominal swelling and pain, haematemesis, or haematochezia. The male to female ratio was 22:9 and the age of onset ranged from 40 to 81 years (median age: 63 years). Tumours were located in the upper and middle third of the stomach (24/31), and in the lower third(7/31). The tumour diameter ranged from 0.6 to 7.3 cm, with an average value of 2.5 cm. Endoscopically, the disease manifested as SMTs, with the gastric mucosal surface appearing normal. Most patients underwent radical gastrectomy for GC (80.6%, 25/31). The pathological diagnoses of the 31 cases of GCSMT included well- and moderately-differentiated adenocarcinoma (6/31), poorly differentiated adenocarcinoma or signet ring cell carcinoma 6/31), mucinous adenocarcinoma (9/31), lymphoepithelioma-like carcinoma (7/31), gastric adenocarcinoma of the fundic gland type (3/31). Stage T1b and T2 tumours accounted for 56.7% (17/30) and 26.7% (8/30) of all cases. Lymph node metastases were found in six cases (20.0%, 6/30), whereas distant metastasis was not observed in any of the cases. For the 16 patients whose follow-up data were available, the follow-up time was 5-66 months, during which recurrence or metastasis was not observed.
UNASSIGNED: GCSMT is a rare disease that is often difficult to accurately diagnose through endoscopic biopsy. The importance of gaining an understanding of this disease lies in differentiating it from other SMTs (mostly mesenchymal tumours) to avoid misdiagnosis and missed diagnosis and enable the early diagnosis and treatment of patients.
UNASSIGNED: The clinical presentation and imaging findings of four GCSMT cases diagnosed at our centre from 2016 to 2021 were observed and their clinicopathological outcomes were analysed. The related literature was reviewed. Based on our collected data and the related literature, a total of 31 cases of GCSMT can be summarized.
UNASSIGNED: 22 out of 31 cases did not present obvious symptoms and were accidentally discovered during gastroscopic examination. Only 10 patients experienced symptoms such as gastric discomfort, upper abdominal swelling and pain, haematemesis, or haematochezia. The male to female ratio was 22:9 and the age of onset ranged from 40 to 81 years (median age: 63 years). Tumours were located in the upper and middle third of the stomach (24/31), and in the lower third(7/31). The tumour diameter ranged from 0.6 to 7.3 cm, with an average value of 2.5 cm. Endoscopically, the disease manifested as SMTs, with the gastric mucosal surface appearing normal. Most patients underwent radical gastrectomy for GC (80.6%, 25/31). The pathological diagnoses of the 31 cases of GCSMT included well- and moderately-differentiated adenocarcinoma (6/31), poorly differentiated adenocarcinoma or signet ring cell carcinoma 6/31), mucinous adenocarcinoma (9/31), lymphoepithelioma-like carcinoma (7/31), gastric adenocarcinoma of the fundic gland type (3/31). Stage T1b and T2 tumours accounted for 56.7% (17/30) and 26.7% (8/30) of all cases. Lymph node metastases were found in six cases (20.0%, 6/30), whereas distant metastasis was not observed in any of the cases. For the 16 patients whose follow-up data were available, the follow-up time was 5-66 months, during which recurrence or metastasis was not observed.
UNASSIGNED: GCSMT is a rare disease that is often difficult to accurately diagnose through endoscopic biopsy. The importance of gaining an understanding of this disease lies in differentiating it from other SMTs (mostly mesenchymal tumours) to avoid misdiagnosis and missed diagnosis and enable the early diagnosis and treatment of patients.
摘要：
未经证实：为了研究临床病理特征，具有粘膜下肿瘤（GCSMT）特征的胃癌（GC）的诊断和鉴别诊断要点。
UNASSIGNED：观察了2016年至2021年在我们中心诊断的4例GCSMT病例的临床表现和影像学表现，并分析了其临床病理结果。对相关文献进行了综述。根据我们收集的数据和相关文献，总共可以总结31例GCSMT.
UNASSIGNED：31例中有22例未出现明显症状，在胃镜检查中意外发现。只有10名患者出现胃部不适等症状，上腹部肿胀和疼痛，呕血,或者便血.男女比例为22：9，发病年龄为40至81岁（中位年龄：63岁）。肿瘤位于胃的上部和中部三分之一（24/31），在下三分之一（7/31）。肿瘤直径0.6～7.3cm，平均值为2.5厘米。内窥镜检查,这种疾病表现为SMTs，胃粘膜表面正常。大多数患者接受胃癌根治术（80.6%，25/31)。31例GCSMT的病理诊断包括高分化腺癌和中分化腺癌（6/31），低分化腺癌或印戒细胞癌6/31），黏液腺癌（9/31），淋巴上皮瘤样癌（7/31），胃底腺型胃腺癌（3/31）。T1b期和T2期肿瘤占所有病例的56.7%(17/30)和26.7%(8/30)。淋巴结转移6例(20.0%,6/30),而在任何病例中均未观察到远处转移。对于有随访数据的16名患者，随访时间5-66个月,在此期间未观察到复发或转移。
UNASSIGNED：GCSMT是一种罕见的疾病，通常很难通过内窥镜活检进行准确诊断。了解这种疾病的重要性在于将其与其他SMT（主要是间充质肿瘤）区分开来，以避免误诊和漏诊，并能够对患者进行早期诊断和治疗。
UNASSIGNED：观察了2016年至2021年在我们中心诊断的4例GCSMT病例的临床表现和影像学表现，并分析了其临床病理结果。对相关文献进行了综述。根据我们收集的数据和相关文献，总共可以总结31例GCSMT.
UNASSIGNED：31例中有22例未出现明显症状，在胃镜检查中意外发现。只有10名患者出现胃部不适等症状，上腹部肿胀和疼痛，呕血,或者便血.男女比例为22：9，发病年龄为40至81岁（中位年龄：63岁）。肿瘤位于胃的上部和中部三分之一（24/31），在下三分之一（7/31）。肿瘤直径0.6～7.3cm，平均值为2.5厘米。内窥镜检查,这种疾病表现为SMTs，胃粘膜表面正常。大多数患者接受胃癌根治术（80.6%，25/31)。31例GCSMT的病理诊断包括高分化腺癌和中分化腺癌（6/31），低分化腺癌或印戒细胞癌6/31），黏液腺癌（9/31），淋巴上皮瘤样癌（7/31），胃底腺型胃腺癌（3/31）。T1b期和T2期肿瘤占所有病例的56.7%(17/30)和26.7%(8/30)。淋巴结转移6例(20.0%,6/30),而在任何病例中均未观察到远处转移。对于有随访数据的16名患者，随访时间5-66个月,在此期间未观察到复发或转移。
UNASSIGNED：GCSMT是一种罕见的疾病，通常很难通过内窥镜活检进行准确诊断。了解这种疾病的重要性在于将其与其他SMT（主要是间充质肿瘤）区分开来，以避免误诊和漏诊，并能够对患者进行早期诊断和治疗。
